Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330017 | 0.89 | IMPDH2 (0.38) | ALOX5IMPDH2IGF1RSRCAXL | |
| SCHEMBL25329338 | 0.87 | IMPDH2 (0.44) | ALOX5IMPDH2IMPDH1 | |
| SCHEMBL25329798 | 0.86 | PTGS2 (0.34) | ALOX5IMPDH2AKR1B1PTGS2 | |
| SCHEMBL25327553 | 0.84 | IMPDH2 (0.36) | ALOX5IMPDH2IMPDH1APPAKR1B1 | |
| SCHEMBL21602868 | 0.83 | IMPDH2 (0.41) | ALOX5IMPDH2IMPDH1 | |
| SCHEMBL32689518 | 0.83 | IMPDH2 (0.41) | ALOX5IMPDH2IMPDH1 | |
| SCHEMBL17431561 | 0.82 | IMPDH2 (0.37) | ALOX5IMPDH2IGF1RSRCAXL | |
| SCHEMBL25331642 | 0.81 | CYP1A2 (0.31) | — | |
| SCHEMBL12190207 | 0.80 | IMPDH2 (0.41) | ALOX5IMPDH2IMPDH1APPAKR1B1 | |
| SCHEMBL25328865 | 0.79 | ALOX5 (0.37) | ALOX5IMPDH2IMPDH1APPAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| EP-4161892-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-04-12 | — | — | EP | disclosed |
| CN-115697954-A | Polymerization inhibitor | 巴斯夫欧洲公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | ALOX5 1518/4885IMPDH2 1168/4885IGF1R 4005/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | ALOX5 560/4885IMPDH2 1852/4885IGF1R 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.